Eli Lilly and vs AstraZeneca: Fair Value & Quality
Both stocks run through our valuation models. Here is how Eli Lilly and (LLY) and AstraZeneca (AZN) compare, as of Aug 13, 2026.
As of Aug 13, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: Eli Lilly and trades at $1,215 versus a fair value of $397 (-67%), while AstraZeneca trades at $159 versus $130 (-18%).
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,215
Fair Value$397
Quality69/100
AstraZeneca
AZN · USD · Health Care
-18%
upside to fair value
overvalued
Price$159
Fair Value$130
Quality69/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Eli Lilly andAstraZeneca
Valuation
42.2×P/E (TTM)26.3×
14.67×P/S (TTM)4.49×
39.94×P/B5.58×
30.2×EV/EBITDA14.5×
1.54×PEG1.36×
0.5%Dividend yield1.8%
$6.23Dividend per share$3.20
Profitability
35%Net margin17%
49%Operating margin28%
107%Return on equity23%
21%Return on assets8%
Growth
56%Revenue growth (YoY)13%
31.7%Avg. growth/yr (3Y)9.8%
21.6%Avg. growth/yr (5Y)17.2%
Balance & size
1.54×Debt / equity0.51×
$1.1TMarket cap$271B
mixedGrowth qualityhealthy
Even match: 7 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Eli Lilly andof which business quality 65 · market factors 84AstraZenecaof which business quality 65 · market factors 52
ProfitabilityMargins and returns on capital today
85
63
Quality GrowthAre margins and returns improving?
86
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
15
60
Low VolatilityCalm price path (market factor)
77
84
MomentumPrice trend over the last 3–12 months (market factor)
81
38
52W MomentumDistance to the 52-week high (market factor)
97
38
Net IssuanceBuybacks instead of dilution
93
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
AstraZeneca
DCF Models$116
Earnings-Based$60.23
Multiples$125
Asset-Based$21.03
Growth DCF$100
Economic Profit$75.73
Growth Earnings$129
22 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,215 = current price (white tick)
AstraZeneca
Bear $73.72Fair Value $130Bull $173
$159 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-67% · bottom 25%
AstraZeneca · Health Care
Quality score69 · Top 25%
Fair value upside-18% · above median
Bottom line
As of Aug 13, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: Eli Lilly and trades at $1,215 versus a fair value of $397 (-67%), while AstraZeneca trades at $159 versus $130 (-18%).
AstraZeneca has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
